Linker effects on biological properties of 111in-labeled DTPA conjugates of a cyclic RGDfK dimer

Bioconjugate Chemistry

Volumn 19, Issue 1, 2008, Pages 201-210

  Jia, Bing ^a,b   Liu, Zhaofei ^a   Shi, Jiyun ^a,b   Yu, Zilin ^a   Yang, Zhi ^c   Zhao, Huiyun ^a   He, Zhengjie ^d   Liu, Shuang ^d   Wang, Fan ^a  

^a PEKING UNIVERSITY   (China)

^b CHINA INSTITUTE OF ATOMIC ENERGY   (China)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^d PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; MAMMALS; TUMORS;

BINDING AFFINITIES; BIOLOGICAL PROPERTIES; CYSTEIC ACIDS; DTPA-CONJUGATES; GLUTAMIC ACID; IN-VITRO; INTEGRINS; POST INJECTION; VITRO AND IN VIVO; VIVO EVALUATION;

AMINO ACIDS;

ARGINYLGLYCYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID PENTETATE INDIUM IN 111 CONJUGATE; CYCLO(ARGINYLGLYCYLASPARTYL FLUOROMETHYL KETONE); CYCLOPEPTIDE; CYSTEIC ACID; DIMER; GLUTAMIC ACID; PENTETATE INDIUM IN 111; SU 016; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER SCINTISCANNING; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG STABILITY; FEMALE; GLIOMA CELL; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; POSITRON EMISSION TOMOGRAPHY; RADIOISOTOPE DISTRIBUTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

MUS; MUS MUSCULUS;

EID: 38949158048     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc7002988     Document Type: Article

References (56)

1. Folkman, J. (2003) Fundamental concepts of the angiogenic process. Curr. Mol. Med. 3, 643-651.
2. Jin, H., and Varner, J. (2004) Integrins: roles in cancer development and as treatment targets. Br. J. Cancer 90, 561-565.
3. Howe, A., Aplin, A. E., Alahari, S. K., and Juliano, R. L. (1998) Integrin signaling and cell growth control. Curr. Opin. Cell Biol. 10, 220-231.
4. Longhurst, C. M., and Jennings, L. K. (1998) Integrin-mediated signal transduction. Cell. Mol. Life Sci. 54, 514-526.
5. Zitzmann, S., Ehemann, V., and Schwab, M. (2002) Arginine-glycine- aspartic acid (RGD)-peptide binds to both tumor and tumor endothelial cells in vivo. Cancer Res. 62, 5139-5143.
6. Weber, W. A., Haubner, R., Vabuliene, E., Kuhnast, B., Webster, H. J., and Schwaiger, M. (2001) Tumor angiogenesis targeting using imaging agents. Q. J. Nucl. Med. 45, 179-182.
7. Van de Wiele, C., Oltenfreiter, R., De Winter, O., Signore, A., Slegers, G., and Dierckx, R. A. (2002) Tumor angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging. Eur. J. Nucl. Med. 29, 699-709.
8. 3. Q. J. Nucl. Med. 47, 209-220.
9. Haubner, R. H., Wester, H. J., Weber, W. A., and Schwaiger, M. (2003) Radiotracer-based strategies to image angiogenesis. Q. J. Nucl. Med. 47, 189-199.
10. 18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjugate Chem. 15, 61-69.
11. 18F-galacto-RGD in cancer patients. J. Nucl. Med. 46, 1333-1341.
12. 18F]Galacto-RGD. PLOS Med. 2 e70, 244-252.
13. 3 directed radiopharmaceuticals for tumor imaging. Drugs of the Future 28, 551-564.
14. 3 antagonists as radiopharmaceuticals for tumor radiotherapy. Top. Curr. Chem. 252, 193-216.
15. 3-targeted radiotracers for tumor imaging. Mol. Pharm. 3, 472-487.
16. Haubner, R., and Wester, H. J. (2004) Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of antiangiogenic therapies. Curr. Pharm. Des. 10, 1439-1455.
17. Wester, H. J., and Kessler, H. (2005) Molecular targeting with peptides or peptide-polymer conjugates: just a question of size. J. Nucl. Med. 46, 1940-1945.
18. 3 expression. Mini Rev. Med. Chem. 6, 227-234.
19. 99mTc-Labeling of a hydrazinonicotinamide- conjugated vitronectin receptor antagonist useful for imaging tumors. Bioconjugate Chem. 12, 624-629.
20. 177Lu-labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy. Bioconjugate Chem. 12, 559-568.
21. 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer. Bioconjugate Chem. 16, 1580-1588.
22. 3 expression. Bioconjugate Chem. 17, 1069-1076.
23. 99mTc- labeled cyclic RGDfK dimer. Bioconjugate Chem. 17, 1499-1507.
24. 3-positive breast cancer. Bioconjugate Chem. 18, 438-446.
25. 99mTc- labeled cyclic RGDfK tetramer. Nucl. Med. Biol. ASAP.
26. 64Cu-labeled dimeric RGD peptides. Mol. Imag. Biol. 6, 350-359.
27. 64Cu-labeled RGD peptide. Bioconjugate Chem. 15, 41-49.
28. 18F-labeled PEGylated RGD peptide. Eur. J. Nucl. Med. Mol. Imaging 31, 1081-1089.
29. 64Cu-labeled tetrameric RGD peptide. J. Nucl. Med. 46, 1707-1718.
30. 18F-FRGD2. J. Nucl. Med. 47, 113-121.
31. 3 integrin binding peptides in a nude mouse model. Cancer Res. 62, 6146-6151.
32. Janssen, M. L., Frielink, C., Dijkgraaf, I., Oyen, W. J., Edwards, D. S., Liu, S., Rajopadhye, M., Massuger, L. F., Corstens, F. H., and Boerman, O. C. (2004) Improved tumor targeting of radiolabeled RGD-peptides using rapid dose fractionation. Cancer Biother. Radiopharm. 19, 399-404.
33. 111In-labeled RGD Peptide. Nucl. Med. Biol. 34, 29-35.
34. 3 integrin by multimerization of RGD peptides. Eur. J. Nucl. Med. Mol. Imaging 34, 267-273.
35. Poethko, T., Schottelius, M., Thumshirn, G., Herz, M., Haubner, R., Henriksen, G., Kessler, H., Schwaiger, M., and Wester, H.-J. (2004) Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation. Radiochim. Acta 92, 317-327.
36. Thumshirn, G., Hersel, U., Goodman, S. L., and Kessler, H. (2003) Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chem. - Eur. J. 9, 2717-2725.
37. Liu, S., and Edwards, D. S. (2001) Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjugate Chem. 12, 7-34.
38. 3 receptor antagonist: different but biologically equivalent. Bioconjugate Chem. 15, 235-241.
39. 90Y-labeled DTPA-biomolecule conjugates. Bioconjugate Chem. 12, 84-91.
40. 111In-labeled DTPA-peptide conjugates. Bioconjugate Chem. 12, 630-634.
41. Camera, L., Kinuya, S., Garmestani, K., Wu, C., Brechbiel, M. W., Pai, L. H., McMurry, T. J., Gansow, O. A., Pastan, I., Paik, C. H., and Carrasquillo, J. A. (1994) Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J. Nucl. Med. 35, 882-889.
42. McMurray, T. J., Pippin, C. G., Wu, C., Deal, K. A., Brechbiel, M. W., Mirzadeh, S., and Gansow, O. A. (1998) Physical parameters and biological stability of yttrium(III) diethylenetriaminepentaacetic acid derivative conjugates. J. Med. Chem. 41, 3546-3549.
43. 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. J. Nucl. Med. 40, 268-276.
44. Camera, L., Kinuya, S., Garmestani, K., Brechbiel, M. W., Wu, C., Pai, L. H., McMurry, T. J., Gansow, O. A., Pastan, I., Paik, C. H., and Carrasquillo, J. A. (1994) Comparative biodistribution of indium- and yttrium-labeled B3 monoalonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz-)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA). Eur. J. Nucl Med. 21, 640-646.
45. 90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumors. Nucl. Med. Biol. 25, 181-188.
46. 3] octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl. Med. Commun. 19, 283-288.
47. Haubner, R., Wester, H. J., Senekowitsch-Schmidtke, R., Diefenbach, B., Kessler, H., Stöcklin, G., and Schwaiger, M. (1997) RGD-peptides for tumor targeting: biological evaluation of radioiodinated analogs and introduction of a novel glycosylated peptide with improved biokinetics. J. Labelled Compd. Radiopharm. 40, 383-385.
48. 3 integrin antagonists: a new class of tracers for tumor imaging. J. Nucl Med. 40, 1061-1071.
49. Haubner, R., Wester, H. J., Burkhart, F., Senekowisch-Schmidtke, R., Weber, W., Goodman, S. L., Kessler, H., and Schwaiger, M. (2001) Glycolated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl Med. 42, 326-336.
50. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61, 1781-1785.
51. Antunes, P., Ginj, M., Walter, M. A., Chen, J., Reubi, J. C., and Maecke, H. R. (2007) Influence of different spacers on biological profile of a DOTA-Somatostatin Analogue. Bioconugate. Chem. 18, 84-92.
52. 3 antagonists for tumor imaging and radiotherapy. Cancer Biother. Radiopharm. 18, 627-641.
53. 99mTc-labeled quinolin-4-one peptidomimetics as ligands for the vitronectin receptor: potential tumor imaging agents. Bioconjugate Chem. 17, 1294-1313.
54. Harris, T. D., Cheesman, E., Harris, A. R., Sachleben, R., Edwards, D. S., Liu, S., Bartis, J., Ellars, C., Onthank, D., Yalamanchili, P., Heminway, S., Silva, P., Robinson, S., Lazewatsky, J., Rajopadhye, M., and Barrett, J. A. (2007) Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging Agents. Bioconjugate Chem. 18, 1266-1279.
55. 125I-labeled RGD peptide are improved by PEGylation. Nucl. Med. Biol. 31, 11-19.
56. 3-targeted imaging of lung cancer. Neoplasia 7, 271-279.